Out with the old, in with the new: An updated risk stratification equation for pulmonary arterial hypertension

Expert Review of Cardiovascular Therapy

Volumn 8, Issue 6, 2010, Pages 739-741

  Thenappan, Thenappan ^a   Gomberg Maitland, Mardi ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; ANOREXIGENIC AGENT; BOSENTAN; ILOPROST; PLACEBO; PROSTACYCLIN; SILDENAFIL; TADALAFIL; UNIPROST; WARFARIN; ANTIHYPERTENSIVE AGENT;

CLINICAL TRIAL; EDITORIAL; HEART FAILURE; HEMODYNAMIC PARAMETERS; HUMAN; MATHEMATICAL COMPUTING; PROGNOSIS; PULMONARY HYPERTENSION; RISK ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME; TREATMENT PLANNING; ALGORITHM; HYPERTENSION, PULMONARY; MORTALITY; SEVERITY OF ILLNESS INDEX; TRENDS;

ALGORITHMS; ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION, PULMONARY; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

EID: 77953499336     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.10.65     Document Type: Editorial

References (22)

1. McLaughlin VV, Archer SL, Badesch DB et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J. Am. Coll. Cardiol. 53(17), 1573-1619 (2009).
2. D'Alonzo GE, Barst RJ, Ayres SM et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann. Intern. Med. 115(5), 343-349 (1991).
3. Rich S, Dantzker R, Ayres S et al. Primary pulmonary hypertension: a national prospective study. Ann. Intern. Med. 107, 216-223 (1987). (Pubitemid 17137857)
4. Sandoval J, Bauerle O, Palomar A et al. Survival in primary pulmonary hypertension. Validation of a prognostic equation. Circulation 89, 1733-1744 (1994).
5. Barst RJ, Galie N, Naeije R et al. Long-term outcome in pulmonary arterial hypertension patients treated with treprostinil. Eur. Respir. J. 28(6), 1195-1203 (2006). (Pubitemid 44883856)
6. Kuhn KP, Byrne DW, Arbogast PG et al. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am. J. Respir. Crit. Care Med. 167(4), 580-586 (2003).
7. McLaughlin VV. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan. Eur. J. Clin. Invest. 36(Suppl. 3), 10-15 (2006).
8. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 106(12), 1477-1482 (2002).
9. McLaughlin VV, Sitbon O, Badesch DB et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur. Respir. J. 25(2), 244-249 (2005).
10. Provencher S, Sitbon O, Humbert M, Cabrol S, Jais X, Simonneau G. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur. Heart J. 27(5), 589-595 (2006).
11. Humbert M, Sitbon O, Chaouat A et al. Pulmonary arterial hypertension in France: results from a national registry. Am. J. Respir. Crit. Care Med. 173(9), 1023-1030 (2006).
12. Thenappan T, Shah SJ, Rich S et al. A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur. Respir. J. 30(6), 1103-1110 (2007).
13. Thenappan T, Shah SJ, Rich S, Tian L, Archer SL, Gomberg-Maitland M. Contemporary survival in patients with pulmonary arterial hypertension: a reappraisal of the National Institutes of Health risk stratification equation. Eur. Respir. J. 35(5), 1079-1087 (2009).
14. Fischler M, Speich R, Dorschner L et al. Pulmonary hypertension in Switzerland: treatment and clinical course. Swiss Med. Wkly 138(25-26), 371-378 (2008).
15. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 131(6), 1917-1928 (2007).
16. Sitbon O, Humbert M, Nunes H et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J. Am. Coll. Cardiol. 40(4), 780-788 (2002).
17. Sitbon O, McLaughlin VV, Badesch DB et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax 60(12), 1025-1030 (2005).
18. Galie N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur. Heart J. 30(4), 394-403 (2009).
19. Macchia A, Marchioli R, Tognoni G et al. Systematic review of trials using vasodilators in pulmonary arterial hypertension: why a new approach is needed. Am. Heart J. 159(2), 245-257 (2010).
20. Sitbon O, Humbert M, Jais X et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111(23), 3105-3111 (2005).
21. Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 123(2), 344-350 (2003).
22. Fisher MR, Mathai SC, Champion HC et al. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum. 54(9), 3043-3050 (2006).